Toripalimab plus Chemotherapy
Phase 2Small molecule
Toripalimab plus Chemotherapy is one of 18 small molecule programs targeting Non-squamous NSCLC. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Non-Squamous NSCLC
#DrugCompanyPhaseTrials
1Alimta
SShawn Eagle
Phase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Avastin
RochePhase 2
Keytruda
Merck & Co.Phase 2
Tecentriq
RochePhase 2
Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Imfinzi
AstraZenecaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details